Overall rank by patents
#11,514
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Xellia Pharmaceuticals Aps
USPTO PatentsView assignee record - 27 granted patents across 16 technology areas, active 2015–2024. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
27
Total patents granted
16
CPC technology areas
16.2
Avg claims per patent
+25%
5-year filing velocity
The verdict
Xellia holds 27 US patents across 16 technology areas, rank #11,514 of 50,000 tracked assignees.
- #11,514
- of 50,000 US assignees by volume
- Top 41%
- by Innovation Score (38.5/100)
- 16.2
- avg claims per patent
- +25%
- filing velocity, last 5 yrs
Portfolio overview
Xellia Pharmaceuticals ApS has been granted 27 US utility patents between 2015 and 2024, placing Xellia Pharmaceuticals ApS at rank #11,514 across all assignees tracked by PlainPatent. This portfolio spans 16 distinct Cooperative Patent Classification (CPC) subclasses, averaging 16.2 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Xellia Pharmaceuticals ApS is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 38.5/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 15 grants, compared with 12 in the 2015–2019 window, a +25% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Xellia Pharmaceuticals ApS's 16.2 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 16 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Xellia Pharmaceuticals ApS against peers pursuing similar technology classes.
How does Xellia compare?
Granted US patents 2015–2025 versus the largest corporate holders, this company marked ◀
- Samsung
SAMSUNG ELECTRONICS CO., LTD.
106,890 patents
- International Bus…
International Business Machines Corporation
72,926 patents
- Canon 34,378
Canon Kabushiki Kaisha
34,378 patents
- LG 32,607
LG ELECTRONICS INC.
32,607 patents
- Taiwan Semiconduc… 31,041
TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY LTD.
31,041 patents
- Apple 30,560
Apple Inc.
30,560 patents
- Qualcomm Incorpor… 30,354
QUALCOMM Incorporated
30,354 patents
- Intel 27,498
Intel Corporation
27,498 patents
- Xellia Pharmaceut… ◀ 27
Xellia Pharmaceuticals ApS
27 patents
What this shows Xellia holds 27 patents, placing it at rank #11,514 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.
Xellia's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
38 Top 41% higher than 59% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
USPTO utility patent grants by year · 2015–2024
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 5 | 18.5% |
| 2016 | 2 | 7.4% |
| 2018 | 1 | 3.7% |
| 2019 | 4 | 14.8% |
| 2020 | 5 | 18.5% |
| 2021 | 4 | 14.8% |
| 2022 | 1 | 3.7% |
| 2023 | 2 | 7.4% |
| 2024 | 3 | 11.1% |
Which technologies does Xellia Pharmaceuticals ApS patent most?
Top 15 of 16 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Standard
Velocity Growing
Frequently Asked Questions
How many patents does Xellia Pharmaceuticals ApS hold?
Xellia Pharmaceuticals ApS holds 27 US granted patents filed between 2015 and 2024, spanning 16 technology areas.
What is Xellia Pharmaceuticals ApS's Innovation Score?
Xellia Pharmaceuticals ApS has an Innovation Score of 38.5 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Xellia Pharmaceuticals ApS focus on?
Xellia Pharmaceuticals ApS's top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 21 patents. The company has filed patents in 16 CPC subclasses total.
Is Xellia Pharmaceuticals ApS's patent filing rate increasing or decreasing?
Xellia Pharmaceuticals ApS's recent filing velocity is +25% compared to the prior five-year period. The company is maintaining or growing its patent output.
What does claim depth mean for Xellia Pharmaceuticals ApS's patents?
Xellia Pharmaceuticals ApS's patents average 16.2 claims each. This falls within the standard range, providing solid legal coverage.
How is the Xellia Pharmaceuticals ApS patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
Guides to patent portfolio analysis
How to use this portfolio
Xellia's 27 grants land it in the top 41% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Xellia ranks #11,514 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Explore the patent dataset
A61P technology
Xellia Pharmaceuticals ApS's primary CPC class, all holders and yearly trends
Top 50 patent holders
See where Xellia Pharmaceuticals ApS ranks among the largest US patent assignees
All technology classes
Browse every CPC technology area by patent activity
How the score works
The four dimensions behind the Innovation Score
Related
Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Data sources used on this page
- USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
- Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
- USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov
